The first drug shown to slow the destruction of the brain in Alzheimer’s disease will not be available on the NHS after a decision by the medicine’s regulator. The decision on funding lecanemab has caused upset and disappointment from those hoping the drug could help fight a horrible and devastating disease. But the decision is … Read more
Getty Images The first drug to slow the progression of early stage Alzheimer’s won’t be available on the NHS in England because health assessment body NICE says the benefits “are too small to justify the costs”. Lecanemab has been licensed by the UK medicines regulator, the MHRA, which means it can be prescribed privately. In … Read more
Getty Images The European Medicines Agency (EMA) has rejected a licence for an Alzheimer’s treatment which slows cognitive decline. The EMA said the benefits of lecanemab did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain. The medicines regulator in the UK, the MHRA, is still considering whether to … Read more
A leading charity says the NHS is unprepared for the rollout of innovative new drugs. Source link
One of the world’s leading researchers behind the whole idea of targeting amyloid 30 years ago, Prof John Hardy, said it was “historic” and was optimistic “we’re seeing the beginning of Alzheimer’s therapies”. Prof Tara Spires-Jones, from the University of Edinburgh, said the results were “a big deal because we’ve had a 100% failure rate … Read more